Note: Ingredients listed on restricted chemical lists
EC/CAS
9003-39-8
Name of the chemical
polyvinylpyrrolidone
Concentration
N/A
EC/CAS
7631-86-9
Name of the chemical
Silver adsorbed on silicon dioxide
Concentration
N/A
EC/CAS
9004-65-3
Name of the chemical
methylhydroxypropylcellulose
Concentration
N/A
EC/CAS
9005-25-8
Name of the chemical
Starch
Concentration
N/A
General Information
Revision date
2021-05-05
Product name
Metformin hydrochloride Extended-Release Tablets USP 500 mg
Product Synonyms
Metformin hydrochloride Extended-Release Tablets USP 500 mg & 1000 mg
Chemical name
N,N-dimethylimidodicarbonimidic diamide hydrochloride
1.2.1 Relevant identified uses
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Manufacturer Name
ScieGen Pharmaceuticals, Inc
Icons in SDS
Company Information
company name
ScieGen Pharmaceuticals, Inc
Section 2
SECTION 2: Hazards identification
Fire and Assume that this product is capable of sustaining combustion. Explosion Health Metformin is contraindicated in patients with renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥1.5 mg/dL [males], ≥1.4 mg/dL [females] or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia. Known hypersensitivity to metformin. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Diabetic ketoacidosis should be treated with insulin. Metformin should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function
